Among the activities proposed by Sinergia are a virtual escape room through the IDIBELL laboratories, family workshops and 360º visits to Bellvitge facilities.
Dr. Fernando Fernández-Aranda is currently the editor-in-chief of the European Eating Disorders Review, a journal that has published a special issue in October focusing on the impact of the pandemic and lockdown on patients with eating disorders and obesity. We spoke with Dr. Fernández-Aranda about this special and the reflections they have extracted.
The impact of the pandemic on people with eating disorders and obesity Read More »
The last month this project, developed by the Catalan Institute of Oncology and IDIBELL, with the collaboration in Portugal of the Pedro Nuñez Institute, has received the awards ” Invertir me Saúde 2020″ and “HINTT Award”.
The European project “Oncommun-ICOnnecta’t” receives two International awards Read More »
The Covid-19 pandemic has created a big social emergency, and research progress is the only solution to face it and control it definitively. From the beginning of the crisis, IDIBELL has adapted to the new needs creating new lines of research to fight the virus and applying all the knowledge to the pandemic.
IDIBELL and its fight against Covid-19 Read More »
An IDIBELL-ICO study has identified that not only that antiangiogenic chemotherapy can induce more aggressiveness and malignancy in kidney tumors, but also, they have identified a biomarker to predict in which patients this may happen. These discoveries are another step towards making cancer therapy more personalized every day.
Drs. Jordi Carratalà, the coordinator of the Infectious Diseases and Transplants Program, and Fernando Fernández Aranda, principal investigator of the Psychiatry and Mental Health Group, both from IDIBELL and the Bellvitge University Hospital, have recently won the respective chairs of the Faculty of Medicine and Sciences of the Health of the University of Barcelona (UB).
The validation of this cellular mechanism will permit the identification of patients who have developed resistance to standard treatments and the implementation of more personalized medicine for prostate cancer.
IDIBELL researcher Josep Maria Aran and his research group will receive 100,000 euros from the aid Product from the AGAUR agency of the Generalitat de Catalunya. They will study two molecules that act on the immune system as possible treatments for autoimmune diseases.
Funding to study new drugs against autoimmune diseases Read More »
The interaction of these two receptors leads to the inhibition of the dopaminergic pathway, which in this disorder is abnormally active. This discovery opens the door to the design of new drugs for the treatment of schizophrenia that acts on this interaction.
The project aims to create online courses that help pre-doctoral researchers to acquire transversal skills for the future of their careers.
IDIBELL receives european funding to promote open science and innovation Read More »
